ISCTM and ECNP | Posters & Presentations

Amsterdam, Netherlands | ISCTM: 9-11th October | ECNP: 11-14th October

We’re excited to announce that our team will be attending the ISCTM 2025 Autumn Conference and ECNP 38th Congress 2025

This year’s program features world-class discussions on precision psychiatry, psychedelic therapies, and lessons from global clinical trials—and we’re proud to be contributing to the conversation.

We’ll be presenting our posters during the dedicated poster session, sharing our latest research and insights with leaders from academia, industry, and regulatory bodies. It’s a fantastic opportunity to exchange ideas, get feedback, and collaborate with experts shaping the future of mental health and neuroscience innovation.

Get ready to explore how our latest findings are pushing the boundaries of what’s possible in early detection, reliable assessment, and effective trial design for neurodegenerative diseases.

Challenges of Central Nervous System (CNS) drug development: evaluation of European Medicines Agency (EMA) rejections and withdrawals by human and Artificial intelligence raters. First Author: Martina De Lillo, PhD

Poster # Thursday, October 9th 2025 – 5:30pm

In this study, we analysed regulatory rejections and withdrawals from the EMA to uncover common pitfalls and systemic challenges in CNS drug development. What makes this research unique is our side-by-side evaluation using both expert human reviewers and AI-driven analysis, highlighting how advanced analytics can complement traditional regulatory assessments.

The findings shed light on:

Key barriers slowing CNS drug approvals, from trial design to endpoint selection.

Trends in regulatory decision-making over recent years.

The potential role of AI in streamlining regulatory reviews and improving prediction of approval outcomes.

Join us during the Poster Session on Thursday, October 9 to explore how combining human expertise and AI can help transform the future of CNS drug development

Cognitive impairment in schizophrenia: mixed-effects meta-analysis of CANTAB computerized assessments of MATRICS domains. First Author: Francesca Cormack, PhD

Poster #PS02-1292 Sunday, October 10th, 2025: 12:35 PM – 2:00 PM EDT

Using data from Cambridge Neuropsychological Test Automated Battery (CANTAB) assessments, we conducted a mixed-effects meta-analysis across multiple studies to examine cognitive performance in key MATRICS domains (such as attention, working memory, and processing speed).

This poster highlights:

How CANTAB’s computerised testing aligns with MATRICS criteria to provide objective, scalable measures.
Insights from a wide body of literature using CANTAB in patients with schizophrenia.
Patterns in impairment across cognitive domains in diverse patient populations.
Insights into cognitive endpoints, helping refine clinical trials addressing cognitive impairment in schizophrenia .

Catch this poster during the Poster Session for ECNP on Sunday, October 12 to see how integrating digital cognitive assessments with rigorous meta-analysis can inform more effective treatment evaluation.